QualityStocksNewsBreaks Archives - Page 628 of 1386

WednesdayMay 26, 2021 12:10 pm

QualityStocksNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Initiation of PALISADE Phase 3 Study of PH94B in SAD

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, is beginning its PALISADE-1 phase 3 trial. The randomized, double-blind, placebo-controlled study is designed to evaluate the efficacy and safety of VTGN’s PH94B (“PH94B”) for the treatment of anxiety in adults with Social Anxiety Disorder (“SAD”). In the announcement, the company noted there is no FDA-approved acute treatment for the disorder. The company plans to include some 200 randomized subjects in the study, which…

WednesdayMay 26, 2021 11:03 am

QualityStocksNewsBreaks – Golden Triangle Ventures Inc. (GTVH) Announces Acquisition of The Lodge Winery & Olive Oil Co.

Golden Triangle Ventures (OTC: GTVH) (“GTV”) today announced the acquisition of The Lodge Winery & Olive Oil Co. under GTV’s Food & Wine Division, Napa Wine Brands Inc. The Lodge Winery & Olive Oil Co. is an established brand that produces award-winning wines, locally grown and milled, single varietal extra virgin olive oils, as well as a variety of award-winning wine vinegars. “Our marketing team is now ready to launch an in-depth program focused on driving our products into big box stores, smaller retail outlets, online platforms and many other avenues,” said Steffan Dalsgaard, CEO of Golden Triangle Ventures. “We…

WednesdayMay 26, 2021 10:23 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces PCT Filing, Bringing Potential to Obtain Patent Coverage in 153 Countries

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed an international patent application that further strengthens its psychedelic derivative drug development candidates across 153 global jurisdictions. Per the update, the application, governed by the Patent Cooperation Treaty (“PCT”), grants Cybin the right to file future national applications into treaty member jurisdictions, including important potential markets for the company. The PCT claims a library of psychedelic derivative drug development candidates. “Technologies gained by Cybin resulting from our strategic acquisition of Adelia Therapeutics, coupled with subsequent research initiatives from our experienced scientific…

WednesdayMay 26, 2021 9:57 am

QualityStocksNewsBreaks – Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) Commences Drilling at Idaho-Based Oakley Project

Excellon Resources (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) today announced the commencement of a 2,800-metre diamond drilling program at the Oakley Project, Idaho in collaboration with Centerra (U.S.) Inc. According to the update, Centerra has the option to earn up to a 70% interest in the project by, among other things, spending up to US$7 million in exploration expenditures prior to May 2026. Under the terms of the option agreement between the parties, Excellon is the manager of the project and Centerra is the operator and currently funds all expenditures. "Oakley is a low-sulphidation, epithermal gold project with the…

WednesdayMay 26, 2021 9:32 am

QualityStocksNewsBreaks – Grapefruit USA Inc. (GPFT) Releases Q1 2021 Financial Numbers, Chooses SRAX Inc. (NASDAQ: SRAX) as Communications Partner

Grapefruit USA (OTCQB: GPFT), a California-based cannabis company, has partnered with SRAX Inc. (NASDAQ: SRAX), an investor relations and communications marketing firm, to strengthen its brand and product line as well as increase awareness of its new e-commerce site and related affiliate program. In the announcement Grapefruit cited SRAX’s novel data-driven approaches to marketing and the company ability to create awareness of stock as key factors in its decision. In addition, the company has filed its quarterly report for the period ended March 31, 2021. The report included disappointing numbers for the company, including net revenues of $350,815, a decrease of…

TuesdayMay 25, 2021 2:47 pm

QualityStocksNewsBreaks – Nextech AR Solutions Corp. (CSE: NTAR) (NEO: NTAR) (OTCQB: NEXCF) (FSE: N29) President Looks to Transformative Potential of AR

Nextech (CSE: NTAR) (NEO: NTAR) (OTCQB: NEXCF) (FSE: N29), a provider of virtual and augmented reality (“AR”) experience technologies and services for e-commerce, education, advertising, conferences and events, is poised to continue growing through the coming years thanks to the disruptive capabilities of AR. A 2017 Harvard Business Review article projected that AR, which at that time was in its infancy, would soon become mainstream and transform various industries. In a podcast interview with Oren Klaff, Nextech president Paul Duffy also gave a positive outlook for the AR market. A recent article quoted him as saying, “The whole concept of…

TuesdayMay 25, 2021 2:36 pm

QualityStocksNewsBreaks – FingerMotion Inc. (FNGR) Strengthening Partnerships with China Telecom Giants

FingerMotion (OTCQX: FNGR), an evolving technology company, is one of only a handful of companies in China with access to wholesale rechargeable minutes from China’s largest mobile phone providers — China Mobile, China Telecom and China Unicom — that can be resold to consumers. By constantly evolving its core competencies in mobile payment and recharge platform solutions in mainland China, FNGR has positioned itself to capitalize on the growth of the telecom market and its relationships with telecommunication companies. According to a recent article, FNGR “is currently working to strengthen the existing and strategic partnerships it has with Chinese telecommunication…

TuesdayMay 25, 2021 1:52 pm

QualityStocksNewsBreaks – Uranium Energy Corp. (NYSE American: UEC) Able to Fully Fund Physical Uranium Initiative

Uranium Energy (NYSE American: UEC), a Texas-based uranium mining and exploration company, was the subject of a recent research report by H.C. Wainwright & Co. (“Wainwright”). The analysts reiterated a buy rating for UEC’s stock, which, as they project, would reach a price target of $5. According to an article reporting the matter, the price projection and the buy rating are “based on a discounted cash flow (‘DCF’) model of future operations and in situ asset values.” Wainwright used a revised discount rate of 7.5%, as well as the value of assets, including Reno Creek ($75.0M), Alto Parana ($41.5M), Paraguay…

TuesdayMay 25, 2021 1:44 pm

QualityStocksNewsBreaks – PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) Unveils Initial Products on Hudson’s Bay Marketplace

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) has launched its first set of products on Hudson’s Bay Marketplace. Included in the product offerings are indoor houseplants; cosmetics and personal care products from Nootka & Sea, one of PlantX Life’s partners; and plant-based pet food from Benevo, Evolution Diet and ami. The announcement noted that the company ultimately plans on expanding its product line to more than 2,000 PlantX products. "Witnessing our agreement with Hudson's Bay Marketplace come to life is beyond encouraging," said PlantX CEO Julia Frank in the press release. "We hope practical ramifications of these efforts will be tangible, and we…

TuesdayMay 25, 2021 1:36 pm

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Expands Team to Add Deep Clinical, Commercial and Regulatory Expertise

Cybin (NEO: CYBN) (OTCQB: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently appointed Alexander Belser as its chief clinical officer and Aaron Bartlone to serve as chief operating officer. Belser and Bartlone bring a wealth of experience and will provide the company with added insight and expertise in the expansion of its development and clinical operations in the U.S. and Europe. A recent article quoted Cybin CEO Doug Drysdale as saying, “These appointments will serve to strengthen our development and clinical operations globally and solidify Cybin’s position within the industry. Alex and Aaron…

Site Search

Company Search

Category: QualityStocksNewsBreaks